Retinal Microperimetry: A Useful Tool for Detecting Insulin Resistance-Related Cognitive Impairment in Morbid Obesity.
cognitive impairment
insulin resistance
morbid obesity
retinal microperimetry
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 Dec 2019
11 Dec 2019
Historique:
received:
28
11
2019
revised:
04
12
2019
accepted:
05
12
2019
entrez:
15
12
2019
pubmed:
15
12
2019
medline:
15
12
2019
Statut:
epublish
Résumé
There is clear association between type 2 diabetes (T2D) and cognitive decline. Retinal microperimetry is a useful tool for detecting cognitive impairment in T2D. Morbid obesity (MO) has been associated with cognitive impairment. Insulin resistance (IR) seems a major determinant, but the data are unclear. The aim of this study was to evaluate the cognitive impairment in MO as well as the utility of retinal microperimetry in identifying these alterations. In total, 50 consecutive patients with MO were matched by age and gender with 30 healthy controls. All patients underwent cognitive evaluation (Montreal Cognitive Assessment Test-MoCA) and retinal microperimetry, using MAIA microperimeter 3rd generation. Retinal sensitivity and gaze fixation parameters were used for the evaluation of the analysis. MO patients showed a significantly lower neurocognitive performance than the controls: MoCA score 24.94 ± 2.74 vs. 28.95 ± 1.05, (1) Systemic insulin resistance is a major underlying mechanism accounting for the higher prevalence of cognitive impairment detected in young MO subjects. (2) Retinal microperimetry is a useful tool for identifying MO patients with cognitive impairment.
Sections du résumé
BACKGROUND
BACKGROUND
There is clear association between type 2 diabetes (T2D) and cognitive decline. Retinal microperimetry is a useful tool for detecting cognitive impairment in T2D. Morbid obesity (MO) has been associated with cognitive impairment. Insulin resistance (IR) seems a major determinant, but the data are unclear. The aim of this study was to evaluate the cognitive impairment in MO as well as the utility of retinal microperimetry in identifying these alterations.
METHODS
METHODS
In total, 50 consecutive patients with MO were matched by age and gender with 30 healthy controls. All patients underwent cognitive evaluation (Montreal Cognitive Assessment Test-MoCA) and retinal microperimetry, using MAIA microperimeter 3rd generation. Retinal sensitivity and gaze fixation parameters were used for the evaluation of the analysis.
RESULTS
RESULTS
MO patients showed a significantly lower neurocognitive performance than the controls: MoCA score 24.94 ± 2.74 vs. 28.95 ± 1.05,
CONCLUSIONS
CONCLUSIONS
(1) Systemic insulin resistance is a major underlying mechanism accounting for the higher prevalence of cognitive impairment detected in young MO subjects. (2) Retinal microperimetry is a useful tool for identifying MO patients with cognitive impairment.
Identifiants
pubmed: 31835729
pii: jcm8122181
doi: 10.3390/jcm8122181
pmc: PMC6947364
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione Internazionale Menarini
ID : 2/2018
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Alzheimers Dis. 2016 Jun 15;53(3):1069-78
pubmed: 27314527
Neurosci Lett. 2011 Mar 17;491(2):122-6
pubmed: 21236314
J Clin Invest. 2012 Apr;122(4):1339-53
pubmed: 22476196
Neuron. 2008 Nov 26;60(4):709-19
pubmed: 19038226
Acta Diabetol. 2017 May;54(5):417-424
pubmed: 28210868
Ann Neurol. 2001 Jan;49(1):53-66
pubmed: 11198297
J Alzheimers Dis. 2013;34(3):649-57
pubmed: 23246920
Trends Endocrinol Metab. 2014 Jan;25(1):23-33
pubmed: 24183659
J Diabetes Complications. 2017 Aug;31(8):1272-1274
pubmed: 28545893
Adv Neurol. 1998;77:49-71; discussion 72-3
pubmed: 9709817
Psychoneuroendocrinology. 2012 Aug;37(8):1270-6
pubmed: 22265870
Metab Brain Dis. 2018 Jun;33(3):615-635
pubmed: 29164373
Invest Ophthalmol Vis Sci. 2014 Aug 26;55(10):6431-9
pubmed: 25159206
Neurobiol Aging. 2010 Aug;31(8):1326-39
pubmed: 20570405
J Clin Invest. 2013 Feb;123(2):531-9
pubmed: 23485579
Prog Retin Eye Res. 2017 Mar;57:89-107
pubmed: 28057562
Exp Physiol. 2017 Dec 1;102(12):1683-1699
pubmed: 28983981
J Alzheimers Dis. 2016;51(2):501-14
pubmed: 26890736
Biol Psychiatry. 2010 Mar 15;67(6):505-12
pubmed: 19358976
Int J Obes (Lond). 2012 May;36(5):656-64
pubmed: 21894161
Diabetes Care. 2013 Feb;36(2):443-9
pubmed: 23069842
Nat Rev Neurosci. 2015 Nov;16(11):660-71
pubmed: 26462756
Radiology. 2019 Jul;292(1):270
pubmed: 31219759
Neurology. 2010 Nov 30;75(22):1982-7
pubmed: 21115952
Diabetes. 2013 Jun;62(6):2112-5
pubmed: 23349494
Exp Gerontol. 2012 Nov;47(11):858-64
pubmed: 22884853
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Obesity (Silver Spring). 2014 Jan;22(1):32-8
pubmed: 23625587
Neurobiol Aging. 2011 Nov;32(11):1942-8
pubmed: 20031276
Front Psychol. 2016 Jul 06;7:1033
pubmed: 27458421
Diabetes Care. 2013 Jan;36(1):90-7
pubmed: 22933440
J Neurophysiol. 2016 Aug 1;116(2):602-10
pubmed: 27169509
Neuropathol Appl Neurobiol. 2016 Jun;42(4):366-76
pubmed: 25967384
J Clin Med. 2019 Jan 08;8(1):null
pubmed: 30626106
PLoS One. 2012;7(1):e30378
pubmed: 22276186
J Alzheimers Dis. 2012;29(4):783-91
pubmed: 22337827
Prog Retin Eye Res. 2015 Sep;48:160-80
pubmed: 25936649
Diabetes. 2017 Dec;66(12):3098-3104
pubmed: 28951388
Front Aging Neurosci. 2018 Jun 22;10:188
pubmed: 29988470
Exp Gerontol. 2017 Feb;88:9-18
pubmed: 28025127
Diabetes Care. 2013 Jan;36(1):137-44
pubmed: 22961577
Prog Retin Eye Res. 2008 Sep;27(5):536-48
pubmed: 18723109
Lancet Diabetes Endocrinol. 2014 Mar;2(3):246-55
pubmed: 24622755
Can J Ophthalmol. 2013 Oct;48(5):358-63
pubmed: 24093180